Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT02579811 trial: what clinicians have said so far
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
- NCT02579811 ↗
- Completed
- Case Comprehensive Cancer Center
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT02579811 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02579811 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study of the Efficacy and Safety of Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer After Treatment With Pd-1 or Pd-L1 Inhibitors
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Metastatic Renal Cell Cancer
- Interventions
- Axitinib
- Arms
- Axitinib · Experimental
- Enrollment
- 40
- Primary outcomes
- Median Progression-free Survival
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Dec 30, 2015
- Primary completion
- Aug 21, 2019
- Results posted
- Yes
- Registry record
- NCT02579811 · updated Jun 29, 2023
Publications
linked from the registry- Ornstein MC, Pal SK, Wood LS, Tomer JM, Hobbs BP, Jia XS, Allman KD, Martin A, Olencki T, Davis NB, Gilligan TD, Mortazavi A, Rathmell WK, Garcia JA, Rini BI. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2019 Oct;20(10):1386-1394. doi: 10.1016/S1470-2045(19)30513-3. Epub 2019 Aug 16. PubMed 31427205